Related Experiment Videos
Thrombotic microangiopathy following allogeneic bone marrow transplantation is associated with intensive
R L Paquette1, L Tran, E M Landaw
1Department of Medicine, UCLA School of Medicine, Los Angeles, CA, USA.
Abstract:
Thrombotic microangiopathy (TM), manifesting clinically as thrombotic thrombocytopenic purpura or hemolytic uremic syndrome, is an uncommon complication after bone marrow transplantation (BMT). A retrospective analysis of potential risk factors for TM following allogeneic BMT was performed. Clinical data were analyzed from seven patients diagnosed with severe TM and 409 patients who underwent BMT during the same time period and who survived for at least 100 days afterwards. Six of the seven patients with TM received intensive GVHD prophylaxis consisting of cyclosporine, methotrexate and glucocorticoids, whereas only 66 of the 409 patients without TM received this regimen (P < 0.001, Fisher's exact test). This regimen was administered to patients older than 40 years, or recipients of a mismatched or unrelated allograft. Univariate analysis also revealed an increased risk of TM associated with the use of an unrelated bone marrow donor (P = 0.02), but no significant association with patient age or gender, diagnosis, amount of prior chemotherapy, transplant conditioning regimen or severity of GVHD. A multivariate exact logistic regression analysis revealed that only the type of GVHD prophylaxis had a significant impact on the risk for TM. The combined use of cyclosporine, methotrexate and glucocorticoids as GVHD prophylaxis may predispose to the development of TM following BMT.
Insights
Intensive graft-versus-host disease (GVHD) prophylaxis, using cyclosporine, methotrexate, and glucocorticoids, may increase the risk of thrombotic microangiopathy (TM) after bone marrow transplantation (BMT). This finding is crucial for understanding TM complications post-BMT.
Area of Science:
- Hematology
- Transplantation Medicine
- Oncology
Background:
- Thrombotic microangiopathy (TM), including thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, is a rare but serious complication following bone marrow transplantation (BMT).
- Identifying risk factors for TM is essential for improving patient outcomes after allogeneic BMT.
Purpose of the Study:
- To investigate potential risk factors associated with the development of severe thrombotic microangiopathy (TM) in patients undergoing allogeneic bone marrow transplantation (BMT).
Main Methods:
- A retrospective analysis was conducted on clinical data from 7 patients diagnosed with severe TM and 409 patients who underwent BMT and survived at least 100 days.
- Statistical analyses, including Fisher's exact test and multivariate exact logistic regression, were used to identify significant risk factors.
Main Results:
- A significantly higher proportion of TM patients (6/7) received intensive graft-versus-host disease (GVHD) prophylaxis (cyclosporine, methotrexate, glucocorticoids) compared to non-TM patients (66/409).
- This intensive GVHD prophylaxis regimen was more common in older patients (>40 years) and recipients of mismatched or unrelated allografts.
- Multivariate analysis confirmed that the type of GVHD prophylaxis was the only significant factor impacting TM risk.
Conclusions:
- The combined use of cyclosporine, methotrexate, and glucocorticoids as GVHD prophylaxis may predispose patients to thrombotic microangiopathy following bone marrow transplantation.
- This finding highlights the importance of considering GVHD prophylaxis strategies in the context of TM risk management post-BMT.